Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity

Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity

PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer

PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer

Receptor protein found to be a key player in prostate cancer cells' drug resistance

Receptor protein found to be a key player in prostate cancer cells' drug resistance

New approach using ultrasound-guided drug delivery effectively targets lymph node metastasis

New approach using ultrasound-guided drug delivery effectively targets lymph node metastasis

Patients with advanced HER2-positive breast cancer live longer if treated with pyrotinib, trial shows

Patients with advanced HER2-positive breast cancer live longer if treated with pyrotinib, trial shows

New treatment breakthrough: Pyrotinib combo demonstrates remarkable efficacy for HER2 positive metastatic breast cancer

New treatment breakthrough: Pyrotinib combo demonstrates remarkable efficacy for HER2 positive metastatic breast cancer

Docetaxel improves survival in men with high-grade prostate cancer and low PSA

Docetaxel improves survival in men with high-grade prostate cancer and low PSA

Modular nanoparticles developed for targeted drug delivery and neutralizing biological agents

Modular nanoparticles developed for targeted drug delivery and neutralizing biological agents

Dato-DXd improves progression-free survival in patients with metastatic non-squamous NSCLC

Dato-DXd improves progression-free survival in patients with metastatic non-squamous NSCLC

Chemotherapy drug may promote cancer growth by injuring surrounding cells

Chemotherapy drug may promote cancer growth by injuring surrounding cells

Adagrasib shows durable clinical activity in KRAS-G12C-mutated NSCLC

Adagrasib shows durable clinical activity in KRAS-G12C-mutated NSCLC

Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C-positive NSCLC at FDA advisory committee meeting

Amgen to discuss application for LUMAKRAS® (sotorasib) for the treatment of KRAS G12C-positive NSCLC at FDA advisory committee meeting

New treatment approach shows promise in reversing hormone resistance in breast cancer

New treatment approach shows promise in reversing hormone resistance in breast cancer

Assessing the role of Docetaxel post-chemoimmunotherapy for patients with NSCLC

Assessing the role of Docetaxel post-chemoimmunotherapy for patients with NSCLC

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

Breast cancer patients experience more severe CIPN symptoms with paclitaxel

Breast cancer patients experience more severe CIPN symptoms with paclitaxel

Scientists to discuss the latest cancer therapies, advances in PSMA PET scans and many more at ASCO

Scientists to discuss the latest cancer therapies, advances in PSMA PET scans and many more at ASCO

Clinical trial of ENZAMET shows promising results for men with advanced prostate cancer

Clinical trial of ENZAMET shows promising results for men with advanced prostate cancer

New funding to accelerate development of potential anti-cancer compound into the clinic

New funding to accelerate development of potential anti-cancer compound into the clinic

Inexpensive combo-chemotherapy found to be better tolerated than BCG for common bladder cancer

Inexpensive combo-chemotherapy found to be better tolerated than BCG for common bladder cancer